title: Limitations of Prostate-specific Antigen Testing After a Prostate Cancer Diagnosis.
abstract: Prostate-specific antigen (PSA) is frequently used in isolation to guide treatment decisions in men with recurrent prostate cancer, a practice discouraged by prostate cancer working groups and guidelines. Instead, PSA should be used with imaging and other factors to make treatment decisions.
authors.affiliation: Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan Medical School, Ann Arbor, MI, USA; Health Services Research and Development Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, MI, USA. Electronic address: mveresh@med.umich.edu.
authors.forename: Megan E V
authors.initials: ME
authors.lastname: Caram
authors.affiliation: Health Services Research and Development Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, MI, USA; Department of Urology, University of Michigan Medical School, Ann Arbor, MI, USA.
authors.forename: Ted A
authors.initials: TA
authors.lastname: Skolarus
authors.affiliation: Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan Medical School, Ann Arbor, MI, USA; Department of Urology, University of Michigan Medical School, Ann Arbor, MI, USA.
authors.forename: Kathleen A
authors.initials: KA
authors.lastname: Cooney
mesh_terms: D000066491:Clinical Decision-Making; D006801:Humans; D008297:Male; D010346:Patient Care Management / Q000458:organization & administration; D017430:Prostate-Specific Antigen / Q000032:analysis*; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000628:therapy
chemical_list: D017430:Prostate-Specific Antigen